For U.S. Residents Only

What is aTTP?

Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare, life-threatening blood disorder. You may hear your doctor or some people refer to it as TTP. This is a general term. The 2 main types of TTP are inherited and acquired; however, 95% of all TTP cases are acquired.

One of the components in your blood that helps your platelets stick together is called von Willebrand factor (vWF). Platelets are small cells found in the blood and are involved in clotting. Their main job is to form blood clots when bleeding happens. Platelets stick together to seal a cut or injury. This stops bleeding. Normally, vWF is cut up into smaller pieces by an enzyme called ADAMTS13.

In people with aTTP, the body’s immune system makes proteins called autoantibodies that stop ADAMTS13 from cutting up vWF.

These large molecules of vWF attract platelets. This forms blood clots even when there is no bleeding. These clots:

  • Can block the flow of blood to important organs, such as the brain, heart, or kidneys. This can cause serious health problems, such as stroke or seizure
  • Can destroy red blood cells, leading to a condition called hemolytic anemia. Because red blood cells carry oxygen, the body doesn’t get as much as it needs. This can make people feel tired and may cause a higher heart rate

What causes aTTP?

It may not be known why someone develops aTTP, but the following could be triggers:

  • Certain disorders or conditions, including cancer, HIV, lupus, infections, or pregnancy
  • Surgery or certain other medical procedures
  • Certain drugs or medications, including chemotherapy, hormone therapy, and estrogen-based medicines (such as oral contraceptives)

Blood flow without aTTP

Blood clot formation in aTTP

What are the signs and symptoms of aTTP?

Everyone’s experience with aTTP is different. You may have had some of the following symptoms. These can be signs of aTTP and could be a warning of having another aTTP episode. This is called a recurrence.

Bleeding-related symptoms

  • Bleeding from the gums or nose
  • Purple bruises (known as purpura) and/or red or purple dots (known as petechiae) on the skin
  • Blood in urine
  • Stomach pain

Blood clot-related symptoms

  • Chest pain
  • Seizures
  • Headaches, confusion, and distorted vision
  • Tiredness and jaundice (a yellowing of the skin and eyes)

Living with aTTP

Learn what to expect

CABLIVI is the first of its kind

Discover how CABLIVI works

The language of aTTP

A diagnosis of aTTP means you may hear new medical terms. Understanding these terms may help you feel more prepared for conversations with your doctor.

What does aTTP stand for?

aTTP (acquired thrombotic thrombocytopenic purpura): Also known as Moschcowitz syndrome, is a rare blood disorder that develops when the immune system stops ADAMTS13, a protein, from working properly. Without this protein, the body creates too many blood clots. This syndrome is characterized by a microangiopathic hemolytic anemia with thrombocytopenia, neurologic symptoms, and renal disease.

Acquired: Describes a condition that is developed later in life. It may be unknown why aTTP was developed.

Thrombotic: Refers to the small blood clots that form inside blood vessels.

Thrombocytopenic: Means having a low platelet count.

Purpura: Red- or purple-colored spots on the skin that do not go away when pressure is applied. It may look like a bruise.

Glossary of aTTP terms

ADAMTS13: An enzyme, or protein molecule, needed to prevent the body from making more blood clots than it needs.

Anemia (uh-NEEM-ee-uh): A drop in the number of red blood cells in the body. Red blood cells carry oxygen throughout the body.

Episode (or Event): An acute period when someone is affected by an illness.

Immune system: The body’s natural defense system against a harmful organism that can make you sick.

Immunosuppressive therapy/Immunosuppressant: Treatment that helps decrease the activity of the immune system, which is overactive during an episode of aTTP.

Intravenous (IV): Entering the body through a vein.

Jaundice: Yellowing of the skin and eyes.

Microthrombi: A blood clot located in a small blood vessel.

Microangiopathic Hemolytic Anemia (MAHA): Anemia caused by destruction of erythrocytes due to physical shearing as a result of passage through small vessels occluded by systemic microthrombi.

Moschcowitz syndrome: More commonly known as Thrombotic thrombocytopenic purpura (TTP), is a primary thrombotic micro-angiopathic disorder which is characterized by the classical "pentad" of fever, thrombocytopenia, micro-angiopathic hemolytic anemia (MAHA), renal failure, and neurological dysfunction.

Petechiae (puh-tEE-kee-ie): Small red or purple spots less than 1/8 of an inch in size on the skin.

Plasma exchange (PEX): A procedure that removes and replaces a person’s blood plasma. This process helps clean the body by removing things it has too much of (such as immune cells) and adding things it has too little of (such as ADAMTS13 and platelets).

Platelets: A small cell found in the blood that is involved in clotting.

Recurrence: Any aTTP episode that follows the first aTTP episode.

Red blood cell: A cell that carries oxygen from the lungs to all parts of the body and then carries carbon dioxide back to the lungs to exhale out of the body.

Specialty pharmacy: A pharmacy that delivers medicines that are not available through a local pharmacy. It often provides services including:

  • Shipping medicine directly to a patient’s home
  • Monthly check-ins with a patient to make sure they’ve completed required testing
  • Being available to answer questions a patient or caregiver may have about receiving medicine

Subcutaneous (SC or subQ): Injected into the body under the skin.

von Willebrand factor (vWF) (vawn vil-uh-brahnt): One of the components in your blood that helps your platelets stick together.

Prepare for your doctor visit by downloading the glossary of terms

Who should not take CABLIVI?

Do not take CABLIVI if you’ve had an allergic reaction to caplacizumab-yhdp or to any of the ingredients in CABLIVI.

What should I tell my healthcare team before starting CABLIVI?
Who should not take CABLIVI?

Do not take CABLIVI if you’ve had an allergic reaction to caplacizumab-yhdp or to any of the ingredients in CABLIVI.

What should I tell my healthcare team before starting CABLIVI?

Tell your doctor if you have a medical condition including if you have a bleeding disorder. Tell your doctor about any medicines you take.
Talk to your doctor before scheduling any surgery, medical or dental procedure.

What are the possible side effects of CABLIVI?

CABLIVI can cause severe bleeding. In clinical studies, severe bleeding adverse reactions of nosebleed, bleeding from the gums, bleeding in the stomach or intestines, and bleeding from the uterus were each reported in 1% of subjects. Contact your doctor immediately if excessive bleeding or bruising occur.
You may have a higher risk of bleeding if you have a bleeding disorder (i.e. hemophilia) or if you take other medicines that increase your risk of bleeding such as anti-coagulants. CABLIVI should be stopped for 7 days before surgery or any medical or dental procedure. Talk to your doctor before you stop taking CABLIVI.
The most common side effects include nosebleed, headache and bleeding gums.
Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of CABLIVI. Call your doctor for medical advice about side effects.

What is CABLIVI?

CABLIVI (caplacizumab-yhdp) is a prescription medicine used for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.

Please see full Prescribing Information
Instructions for Use
Sharps Medical Waste Disposal (PDF)

Click here to learn more about Sanofi’s commitment to fighting counterfeit drugs.